Incyte Corp

-$0.97 (-1.3%)
Closing price July 27, 2021
These are five stocks that the top hedge funds are buying, none of which is an overbought and crowded tech stock. They all make good sense for growth accounts with some risk tolerance.
The include top analyst upgrades, downgrades and other research calls from Wednesday Akamai Technologies, Apple, AutoZone, Dropbox, Electronic Arts, Ford, Kinder Morgan, Pandora Media, Procter &...
Tuesday was a positive day for the broad U.S. markets with each of the major exchanges recovering, if only slightly, from Monday. Crude oil was pushed much higher in the session, retreating over $70....
Incyte and Eli Lilly will be under the microscope next week as the FDA will decide the fate of their rheumatoid arthritis treatment.
Thursday was another positive day for the broad U.S. markets. Although markets were solid throughout the day, there was a small dip at the end from some selling pressure. At the same time, crude oil...
Acadia Pharmaceuticals, Veo, Sibanye Gold, and Incyte Pharmaceuticals all posted new 52-week lows Monday.
The top analyst upgrades, downgrades and other research calls from Monday include Alcoa, CEMEX, Comerica, Facebook, General Motors, Incyte, Proofpoint and Regeneron Pharmaceuticals.
24/7 Wall St. perused all 86 picks from the Credit Suisse top picks list and picked out the few names that are still targeting upside of more than 50%.
Incyte, NewLink Genetics, McDermott International, and Williams Companies all posted new 52-week low Friday.
Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage collaboration with Merck. NewLink Genetics felt the sting as well.
Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
Thursday was a strong day for the U.S. markets, with all three of the major exchanges hitting all-time highs yet again. Earnings season is just around the corner, and starting Friday we will finally...
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney and Windstream.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should a study be...
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.